Literature DB >> 29149378

[Ocular sarcoidosis : Diagnosis and therapy].

E Gundlach1, B Temmesfeld-Wollbrück2, U Pleyer3.   

Abstract

Sarcoidosis is a multisystem disorder of unknown cause. Ophthalmic involvement occurs in up to 60% of all patients, often as the first manifestation of sarcoidosis. Because of the heterogeneous clinical presentation diagnosis can be difficult; therefore the International Workshop on Ocular Sarcoidosis (IWOS 2009) diagnostic criteria based on clinical presentation, laboratory investigations and imaging techniques enable establishment of the diagnosis. Patients suffering from sarcoidosis should be treated by both ophthalmologists and internal physicians. Corticosteroids are commonly used for treatment, although in some patients the therapy has to be escalated by further immunosuppressants. Finally, a good cooperation between ophthalmologists and internal physicians results in a mostly good prognosis.

Entities:  

Keywords:  Boeck’s disease; Corticosteroids; Granulomatous inflammation; Multisystem disease; Uveitis

Mesh:

Substances:

Year:  2017        PMID: 29149378     DOI: 10.1007/s00347-017-0552-5

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  14 in total

Review 1.  Ocular involvement in sarcoidosis.

Authors:  A Rothova
Journal:  Br J Ophthalmol       Date:  2000-01       Impact factor: 4.638

Review 2.  [Sarcoidosis].

Authors:  S Pabst; D Skowasch; C Grohé
Journal:  Pneumologie       Date:  2012-02-15

3.  BTNL2 gene variant and sarcoidosis.

Authors:  Y Li; B Wollnik; S Pabst; M Lennarz; E Rohmann; A Gillissen; H Vetter; C Grohé
Journal:  Thorax       Date:  2006-03       Impact factor: 9.139

Review 4.  The Diagnosis, Differential Diagnosis, and Treatment of Sarcoidosis.

Authors:  Antje Prasse
Journal:  Dtsch Arztebl Int       Date:  2016-08-22       Impact factor: 5.594

5.  Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK.

Authors:  J Gribbin; R B Hubbard; I Le Jeune; C J P Smith; J West; L J Tata
Journal:  Thorax       Date:  2006-07-14       Impact factor: 9.139

Review 6.  Sarcoidosis.

Authors:  Dominique Valeyre; Antje Prasse; Hilario Nunes; Yurdagul Uzunhan; Pierre-Yves Brillet; Joachim Müller-Quernheim
Journal:  Lancet       Date:  2013-10-01       Impact factor: 79.321

7.  Methotrexate vs azathioprine in second-line therapy of sarcoidosis.

Authors:  Adriane D M Vorselaars; Wim A Wuyts; Veronique M M Vorselaars; Pieter Zanen; Vera H M Deneer; Marcel Veltkamp; Michiel Thomeer; Coline H M van Moorsel; Jan C Grutters
Journal:  Chest       Date:  2013-09       Impact factor: 9.410

Review 8.  Sarcoidosis: immunopathogenetic concepts and their clinical application.

Authors:  J Müller-Quernheim
Journal:  Eur Respir J       Date:  1998-09       Impact factor: 16.671

9.  International criteria for the diagnosis of ocular sarcoidosis: results of the first International Workshop On Ocular Sarcoidosis (IWOS).

Authors:  Carl P Herbort; Narsing A Rao; Manabu Mochizuki
Journal:  Ocul Immunol Inflamm       Date:  2009 May-Jun       Impact factor: 3.070

10.  Interleukin-2 Receptor and Angiotensin-Converting Enzyme as Markers for Ocular Sarcoidosis.

Authors:  Enken Gundlach; Michael Marcus Hoffmann; Antje Prasse; Sonja Heinzelmann; Thomas Ness
Journal:  PLoS One       Date:  2016-01-22       Impact factor: 3.240

View more
  3 in total

1.  [Placoid chorioretinal foci of inflammation in combination with prominent hili].

Authors:  Annabelle Eckert; Tilmann Kallinich; Uwe Pleyer
Journal:  Ophthalmologe       Date:  2018-11       Impact factor: 1.059

Review 2.  [Association of the different forms of uveitis with inflammatory rheumatic diseases and their treatment].

Authors:  Nicole Stübiger; Sanaz Farrokhi; Yannik Gkanatsas; Christoph Deuter; Ina Kötter
Journal:  Z Rheumatol       Date:  2022-08-30       Impact factor: 1.530

3.  Findings and Graduation of Sarcoidosis-Related Uveitis: A Single-Center Study.

Authors:  Lynn S Zur Bonsen; Dominika Pohlmann; Anne Rübsam; Uwe Pleyer
Journal:  Cells       Date:  2021-12-29       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.